Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

PHSZX PGIM Jennison Health Sciences Z

  • Fund
  • PHSZX
  • Price as of: May 22, 2019
  • $46.64 + $0.02 + 0.04%
  • Category
  • Health & Biotech Equities

PHSZX - Profile

Vitals

  • YTD Return 9.5%
  • 3 Yr Annualized Return 6.2%
  • 5 Yr Annualized Return 1.5%
  • Net Assets $2.06 B
  • Holdings in Top 10 35.4%

52 WEEK LOW AND HIGH

$46.64
$39.31
$59.83

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.85%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 36.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of Jun 29, 2012

STANDARD (TAXABLE)

$5,000,000

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 9.5%
  • 3 Yr Annualized Total Return 6.2%
  • 5 Yr Annualized Total Return 1.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.34%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name PGIM Jennison Health Sciences Fund
  • Fund Family Name PGIM Funds (Prudential)
  • Inception Date Jun 30, 1999
  • Shares Outstanding N/A
  • Share Class Inst
  • Currency USD
  • Domiciled Country United States
  • Manager David Chan

Fund Description

The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.

PHSZX - Performance

Return Ranking - Trailing

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
YTD 9.5% -4.3% 27.1% 29.41%
1 Yr -10.6% -23.4% 7.2% 83.33%
3 Yr 6.2%* -16.9% 24.9% 31.37%
5 Yr 1.5%* -11.4% 18.4% 47.96%
10 Yr 11.4%* -1.8% 16.1% 30.86%

* Annualized


Return Ranking - Calendar

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
2018 -13.5% -25.3% 7.7% 76.47%
2017 25.8% -10.8% 43.9% 13.73%
2016 -17.2% -29.8% 2.6% 65.69%
2015 -7.3% -20.4% 13.8% 78.43%
2014 19.3% -5.8% 31.5% 34.69%

Total Return Ranking - Trailing

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
YTD 9.5% -4.3% 27.1% 29.41%
1 Yr -10.6% -23.4% 11.3% 84.31%
3 Yr 6.2%* -16.9% 28.1% 47.06%
5 Yr 1.5%* -11.4% 20.4% 71.43%
10 Yr 11.4%* -1.8% 18.6% 54.32%

* Annualized


Total Return Ranking - Calendar

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
2018 -13.5% -25.3% 12.3% 79.41%
2017 25.8% -10.8% 45.8% 16.67%
2016 -17.2% -24.2% 8.7% 77.45%
2015 -7.3% -16.6% 15.2% 82.35%
2014 19.3% -5.8% 36.7% 64.29%

NAV & Total Return History

PHSZX - Holdings

Concentration Analysis

PHSZX Category Low Category High PHSZX % Rank
Net Assets 2.06 B 13.9 M 44.3 B 35.29%
Number of Holdings 93 28 362 42.16%
Net Assets in Top 10 725 M 7.98 M 18.8 B 36.27%
Weighting of Top 10 35.35% 24.7% 76.6% 82.35%

Top 10 Holdings

  1. Illumina Inc 4.92%

  2. Biomarin Pharmaceutical Inc 4.60%

  3. Sage Therapeutics Inc 4.59%

  4. Sarepta Therapeutics Inc 3.93%

  5. UnitedHealth Group Inc 3.24%

  6. Intuitive Surgical Inc 3.00%

  7. AstraZeneca PLC ADR 2.95%

  8. Alexion Pharmaceuticals Inc 2.81%

  9. Exact Sciences Corp 2.76%

  10. Boston Scientific Corp 2.55%


Asset Allocation

Weighting Return Low Return High PHSZX % Rank
Stocks
97.96% 92.71% 99.87% 73.53%
Cash
1.88% 0.00% 7.28% 19.61%
Other
0.17% -1.35% 3.29% 40.20%
Preferred Stocks
0.00% 0.00% 2.00% 21.57%
Convertible Bonds
0.00% 0.00% 0.12% 7.84%
Bonds
0.00% 0.00% 0.09% 15.69%

Stock Sector Breakdown

Weighting Return Low Return High PHSZX % Rank
Healthcare
95.95% 13.80% 99.84% 67.65%
Technology
1.65% 0.00% 61.10% 30.39%
Industrials
0.29% 0.00% 10.61% 28.43%
Utilities
0.00% 0.00% 0.00% 5.88%
Real Estate
0.00% 0.00% 2.13% 16.67%
Financial Services
0.00% 0.00% 3.44% 29.41%
Energy
0.00% 0.00% 0.08% 8.82%
Communication Services
0.00% 0.00% 0.00% 5.88%
Consumer Defense
0.00% 0.00% 0.40% 14.71%
Consumer Cyclical
0.00% 0.00% 7.87% 22.55%
Basic Materials
0.00% 0.00% 0.47% 16.67%

Stock Geographic Breakdown

Weighting Return Low Return High PHSZX % Rank
US
88.26% 62.33% 99.20% 34.31%
Non US
9.70% 0.00% 37.50% 66.67%

PHSZX - Expenses

Operational Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.85% 0.10% 2.98% 81.37%
Management Fee 0.72% 0.09% 1.25% 50.98%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.01% 0.40% N/A

Sales Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 36.00% 0.00% 699.00% 39.22%

PHSZX - Distributions

Dividend Yield Analysis

PHSZX Category Low Category High PHSZX % Rank
Dividend Yield 0.00% 0.00% 0.01% 24.51%

Dividend Distribution Analysis

PHSZX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Annually Annually

Dividend Payout History


Net Income Ratio Analysis

PHSZX Category Low Category High PHSZX % Rank
Net Income Ratio -0.34% -2.15% 1.48% 53.92%

Capital Gain Distribution Analysis

PHSZX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

PHSZX - Managers

David Chan

Manager

Start Date

Tenure

Tenure Rank

Jun 30, 1999

19.85

19.9%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.


Debra Netschert

Manager

Start Date

Tenure

Tenure Rank

Jan 28, 2015

4.25

4.3%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.


Tenure Analysis

Category Low

0.09

Category High

21.64

Category Average

10.34

Category Mode

19.01